Enzo Biochem Inc. (NYSE:ENZ) traded up 3.6% during trading on Tuesday . The stock traded as high as $6.07 and last traded at $6.07, with a volume of 160,522 shares. The stock had previously closed at $5.86.

Separately, Zacks Investment Research cut shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th.

The stock has a 50 day moving average of $6.40 and a 200-day moving average of $5.40. The company has a market cap of $275.73 million and a PE ratio of 15.60.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings results on Wednesday, June 8th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The company earned $18.16 million during the quarter, compared to the consensus estimate of $24.50 million. During the same quarter last year, the company earned ($0.07) earnings per share. Analysts expect that Enzo Biochem Inc. will post ($0.23) earnings per share for the current year.

Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.